ABBV changes
Pick any two versions below to diff them.
- Price
- $291.31 → $294.98(+1.3%)
- Recent events
- Oct 30, 2026: AbbVie reported Q3 2026 results. Net revenues grew 10.3% to $17.404 billion. Immunology grew 16.3%, with Skyrizi up 22.7% to $5.776 billion and Rinvoq up 23.9% to $2.706 billion, while Humira fell 31.2%. Neuroscience grew 19.4%, oncology grew 0.8% and aesthetics fell 1.4%. Adjusted diluted EPS was $3.82. AbbVie raised its 2026 adjusted EPS guidance to $13.95 to $13.99 and raised the quarterly dividend 5.2% to $1.82 per share from February 2027. Oct 30, 2026: In the Q3 2026 release, AbbVie said that the FDA approved Juvmo (tavapadon) for Parkinson's disease and Skyrizi for subcutaneous induction in Crohn's disease. It submitted a Biologics License Application for etentamig in multiple myeloma. Lutikizumab met its primary endpoint in a Phase 3 study in hidradenitis suppurativa. Oct 29, 2026: A US district court in Washington, D.C. vacated the selection of Botox for Medicare price negotiation and blocked CMS from publishing a maximum fair price for Botox. The government can appeal the ruling. added: Oct 27, 2026: AbbVie submitted etentamig to the FDA for adults with relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, etentamig improved the response rate and the time without disease progression against standard therapies. Oct 22, 2026: Lutikizumab met its main goal in the Phase 3 INTREPID study in moderate to severe hidradenitis suppurativa. At week 16, 31.4% of patients on lutikizumab reached the HiSCR75 response, against 23.4% on placebo, with no new safety concerns. Oct 5, 2026: AbbVie said that Q3 2026 results include $216 million of acquired IPR&D and milestones expense, or $0.11 per share, and set its 2026 adjusted EPS guidance at $13.76 to $13.96 after this cost. Sep 3, 2026: AbbVie completed its purchase of Apogee Therapeutics for $135.11 per share in cash, a total equity value of about $10.9 billion. Apogee's lead drug, zumilokibart, is a long-acting antibody against IL-13 for atopic dermatitis. Aug 18, 2026: AbbVie issued $10.0 billion of senior notes, with maturities from 2028 to 2066, to pay for the Apogee purchase. Jul 31, 2026: AbbVie reported Q2 2026 results. Net revenues grew 10.2% to $16.990 billion, and adjusted diluted EPS grew 22.9% to $3.65. It included the dilution from Apogee in its 2026 guidance. Jun 22, 2026: AbbVie agreed to buy Apogee Therapeutics to add drugs for atopic dermatitis and asthma to its immunology pipeline. Mar 4, 2026: AbbVie issued $8.0 billion of senior notes, with maturities from 2028 to 2066. In February 2026, Moody's raised AbbVie's senior unsecured rating to A2 with a stable outlook. Feb 4, 2026: AbbVie reported 2025 results. Net revenues grew 8.6% to $61.160 billion. Adjusted diluted EPS was $10.00, after a cost of $2.76 per share for acquired IPR&D and milestones.